@peter_torngren@fdzmurillo My conviction in $NVO increases day by day seeing their Wegovy franchise build-out. Have been adding another 10% to my position at opening today. Long $NVO.
@TheRayMyers Soon many will be disappointed to not have invested more in $NVO. This market share forecast figure didn't include today's knowledge of the fastest drug launch ever by $NVO, who is not just recovering but taking back market share, while the market is still largely untapped:
@FinanceDocUK The opposite. I think soon many will be disappointed to not have invested more in $NVO. This market share forecast figure didn't include today's knowledge of the fastest drug launch ever by $NVO:
@Redpulse_News Let's see whether soon many will be disappointed to not have invested more in $NVO. The market share forecast figure didn't include the fastest drug launch ever by $NVO (quiet hint π):
@MichaelAlbertMD Thanks for sharing! Another indication that NVO is not just recovering, but taking back market share. $NVO's scale, Wegovy franchise and ecosystem is coming to fruition. Long $NVO. @investseekers@KontraInvest
@realroseceline Trump bought $NOW. This apparently changes the whole perspective of investors (read: traders) these days and Software is again the essential layer for AI, which it has always been π
@Quality_stocksA Accenture will have a lot more work because of AI. $ACN will support the risk-averse institutions, passing security/compliance reviews, integrating with legacy systems, training staff, and earning enough trust to become deeply embedded in workflows. Coding was the moat.
@FluentInQuality Similar as with $NVO. It's not a 'one product fits all' market, with Zoetis being the dominant player in this still largely untapped and growing market. $ZTS will be fine.